These subtypes are known to predict differential responses to
emerging targeted therapies, but they are cumbersome to measure accurately and require biopsies.
Not exact matches
This is important because it makes it possible to model almost any autoimmune disease, evaluate new drug
therapies, and even identify novel
targets in the
emerging area of cancer immunotherapies.
Nonalcoholic fatty liver disease (NAFLD)-- induced hepatocellular carcinoma (HCC) is an
emerging malignancy in the developed world; however, mechanisms that contribute to its formation are largely unknown, and
targeted therapy is currently not available.
This webinar is the third in a series focusing on the cancer pathways that support tumor development, the
emerging research in identifying and
targeting these pathways, and innovations in the development of increasingly effective cancer
therapy options.
This webinar is the second in a series (see Part 1 here) focusing on the cancer pathways that support tumor development, the
emerging research in identifying and
targeting these pathways, and innovations in the development of increasingly effective cancer
therapy options.
Thus, finding new
targets for drugs already in use to treat other diseases, in other words drug repurposing, is an
emerging area in developing anti-cancer
therapies.
«Thanks to improvements in the understanding of AML biology, a multiplicity of so - called
targeted therapies and
therapies based on differential pathophysiology of leukemic stem cells compared with normal counterparts have
emerged,» noted Richard M. Stone, MD, clinical director of the Adult Leukemia Program at Dana - Farber Cancer Institute in Boston, and colleagues, writing in a review for the ASCO 2017 Educational Book.
It is perhaps reasonable to think that it should be the primary
target based on the evidence to date, and Spiegel is optimistic that useful
therapies will
emerge, but de Grey is cautious, and Bains somewhat unhappy about the poor quality of some past research on this topic.
«It is our hope that
emerging technologies and future studies will expand on our work, and ultimately lead to safe,
targeted, and cost - effective
therapies that markedly improve visual outcomes and quality of life for patients suffering from these debilitating eye diseases.»
The approach is to use clinically relevant tumor models such as patient - derived xenografts (PDXs), as well as humanized and immunocompetent transgenic tumor - bearing mice to design rational combinations of novel and
emerging cancer
therapies, including tumor -
targeting and immune - stimulating
therapies, to ultimately improve treatment outcomes for cancer patients.
My work is in the
emerging field called:
Targeted Cancer
Therapy (TCT).
Myelosuppression is a well - established side effect of current AML
therapies, with prolonged events leading to an increased risk of infections and death.44 Consequently,
therapies that preferentially kill leukemic cells over normal bone marrow cells are urgently required, and the overexpression of CD123 on AML leukemic stem cells and blasts compared with normal hematopoietic cells contributes to its attractiveness as a therapeutic
target in this disease.6, 45 However, severe myelosuppression and myeloablation have
emerged for some investigational CD123 -
targeted treatment modalities.
Other existing and
emerging treatment options for animals with cancer include
targeted molecular
therapy, immunotherapy, hyperthermia, cryotherapy, phototherapy, photochemotherapy, thermochemotherapy and other
emerging unconventional or alternative
therapies.